Alexion

pivot change turnaround direction walk away
Biotech

AstraZeneca CEO defends 'fantastic' Alexion buy as halts drug

AstraZeneca ended development of vemircopan, triggering a $753 million charge as the drugmaker reevaluated the worth of its Alexion acquisition.
scrapheap

AZ licenses discarded rare disease drug to Monopar Therapeutics

Oct 24, 2024 2:54pm
Illustration connected puzzle pieces with the acronym MA

AstraZeneca inks $800M buyout to snag phase 3 rare disease drug

Mar 14, 2024 9:47am
spring slinky competition overtake crush absorb

SpringWorks eyes AstraZeneca's Koselugo market with phase 2 data

Nov 16, 2023 10:59am
Graphic of a spaceship landing on Mars surface

Voyager asset lands on planet Alexion after Pfizer handoff

Nov 6, 2023 4:01pm
Photo of a ballerina striking a pose at the center of the stage while the crowd watches

Novartis’ iptacopan has ‘faultless’ performance in phase 3

Oct 2, 2023 11:09am